Our Team

Our Team

Inspirational Leadership Team and Expert Advisors Guiding Strategic Growth

Novadip’s highly experienced management team has a deep knowledge of science, regulation and development pathways, as well as a proven track record in significant fundraising for regenerative medicine companies. The team is committed to advancing our 3M3 tissue regeneration platform to accelerate healing through single treatment cures.

Executive Leadership Team

Denis Dufrane, MD, PhD

Co-Founder, Chief Executive Officer
& Board Member

Judy Ashworth, MD

Chief Medical Officer

Virginie Cartage

Chief Financial Officer

Hara Episkopou, PhD

Head of Discovery

Siegfried Ebner, PhD

Chief Operations Officer

Gaëtane Metz,

VP Quality

Justine Fourmeau

VP Clinical Manufacturing

Board of Directors

Eric Paul Pâques, PhD

Chairman

Gil Beyen, MBA

Independent Board Member

Jean-Pierre Bizet, PhD

New Science Ventures

Philippe Durieux

Vives Partners

Patrick Van Beneden

 

Jason Zhou, MBBS, MBA

China Resources

Christina Franssen, PhD

SRIW

Clinical & Scientific Advisory Board

Gunnar B. J. Andersson MD, PhD

Chairman, Clinical Advisory Board

Aaron W. James, MD, PhD

Chairman, Scientific Advisory Board

Our Science

Novadip is committed to advancing our 3M3 tissue regeneration platform to accelerate healing through single treatment cures.

Our Pipeline

Our robust pipeline of treatments is designed with patient need in mind—where can we make the most difference and help patients with devastating conditions impacting quality of life. We’re poised to make a difference in the lives of patients who are in need of spinal fusion surgeries, for those who have undergone tumor removal for cancers, difficult healing fractures, and more.